{"brief_title": "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", "brief_summary": "This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.", "condition": ["Secondary Hyperparathyroidism", "End Stage Renal Disease"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Placebo", "AMG 073"], "description": ["30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally", "30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally"], "arm_group_label": ["Placebo", "AMG 073"], "criteria": "Patients must be receiving hemodialysis; have elevated parathyroid hormone levels; not be pregnant or nursing; and not have had a heart attack in the last 3 months.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Neoplasm Metastasis", "Kidney Failure, Chronic", "Hyperparathyroidism", "Hyperparathyroidism, Secondary", "Cinacalcet Hydrochloride"], "id": "NCT00042653"}